New app offers diabetes information with dash of humor
SALT LAKE CITY — One of the basic functions of humor is to make people feel better about difficult situations. A group of software developers has incorporated that idea into a new app for Apple iPhones, iPods and iPads for people living with diabetes.
The app, called “Shot in the Arm,” made by Nashsmile, delivers brief and simple diabetes management advice, as well as humor — for example, ways to handle an insulin reaction and jokes, such as “Whoever said ‘no man is an island’ has never seen my stomach in the bath tub.”
“The ideas come at exactly the right time,” Richard Nash of Nashsmile said. Nash has had Type 1 diabetes for 42 years. “You check your phone one morning, you read a brief, simple idea to help you control your diabetes, you try it that day, it works — and all of a sudden, it’s not a diabetes management tip from a book or website. It’s a part of your life.”
OCuSOFT announces availability of Ocudox Convenience Kit
RICHMOND, Texas — A prescription-only eyelid disease treatment kit is available at retail pharmacies around the country, the kit’s manufacturer said.
OCuSOFT announced the availability of the Ocudox Convenience Kit for immediate dispensing at such retail pharmacies as Rite Aid, CVS, Walgreens — including Duane Reade — among others.
The kit includes Ocudox capsules (doxycycline hyclate), OCuSOFT Lid ScrubPLUS Extra Strength Pre-Moistened Pads and Tears Again advanced Liposome Spray. The kit includes antibacterial properties designed to eliminate bacteria strains, such as MRSA and Staph epi1.
AmerisourceBergen posts 2.4% increase in revenue
VALLEY FORGE, Pa. — AmerisourceBergen on Thursday posted revenue of $19.8 billion, up 2.4%, for its second quarter ended March 31.
"In the March quarter, we delivered outstanding performance on top of very strong performance last year," stated David Yost, AmerisourceBergen CEO.
"Solid results in all of our business units, combined with better than expected contributions from specialty generics drove results ahead of expectations,” added Steve Collis, AmerisourceBergen president and COO. “Our disciplined working capital management has further strengthened our balance sheet, and we continue to have excellent financial flexibility. Our results continue to demonstrate the strength of our two growth drivers: generics and specialty pharmaceuticals."
Earlier in the quarter, Yost announced his retirement. He will be succeeded by Collis.
AmerisourceBergen also updated its guidance — projecting diluted earnings per share in fiscal year 2011 will be in the range of $2.41 to $2.49.
"The key assumptions supporting the diluted earnings per share range for fiscal year 2011 are: We continue to expect revenue growth of between 2% and 4%, we now expect operating margin expansion in the mid to high single-digit basis points range, and free cash flow is now expected to be in the high end of the range of $625 million to $700 million, which includes capital expenditures now expected to be in the $175 million range,” Yost said. “We have increased our share repurchase expectation for fiscal year 2011 to $598 million from the original expectation of $400 million for the year, subject to market conditions."